Stocks
Biogen Inc.BIIB
NASDAQHealthcareBiotechnology$181.55-1.81%
A biotechnology company focused on therapies for neurological and neurodegenerative diseases, including multiple sclerosis, Alzheimer’s disease, and spinal muscular atrophy. Its revenue base has historically been driven by MS treatments, while newer Alzheimer’s drugs and a late‑stage pipeline are cl...
Market Cap: $26.6B52W Range: $110.04 – $202.41
Congressional Interest in Biogen Inc. (BIIB)
18 members of Congress have disclosed 50 trades in Biogen Inc. (BIIB), a Healthcare company. The buy/sell breakdown shows 22 purchases versus 28 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
18
Buys
22
Sells
28
Who in Congress Is Trading BIIB?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-03-17 | Josh Gottheimer | sell | $1K – $15K |
| 2022-01-14 | Kathy Manning | sell | $1K – $15K |